Type 2 diabetes is hallmarked by insulin resistance and insufficient b-cell function. Islets of type 2 diabetes patients have been shown to have decreased hypoxia-inducible factor (HIF)-1a/b expression. Target genes of the HIF pathway are involved in angiogenesis, survival, proliferation, and energy metabolism, and von Hippel-Lindau protein (VHL) is a negative regulator of this pathway. We hypothesized that increased HIF-mediated gene transcription by VHL deletion in the b-cells would increase b-cell mass and function. We generated b-cell-specific VHL-knockout mice using the Cre-loxP recombination system driven by the rat insulin promoter to assess the role of VHL in glucose homeostasis and b-cell function. VHL deletion in the pancreatic b-cells led to impaired glucose tolerance due to defects in glucose-stimulated insulin secretion and b-cell mass with age. VHL-knockout islets had decreased GLUT2, but increased glucose transporter 1 and vascular endothelial growth factor expression. Furthermore, there were significant aberrations in islet morphology in the VHL-knockout mice, likely due to increased islet vasculature. Given that erythropoietin (EPO) is a target gene of the HIF pathway, which is not expressed in islets, we tested whether activating EPO signaling by systemic administration with recombinant human EPO (rHuEPO) can overcome the b-cell defects that occurred with VHL loss. We observed improved glucose tolerance and restoration of GLUT2 expression in VHL-deficient b-cells in response to rHuEPO. Contrary to our hypothesis, loss of VHL and increased transcription of HIF-target genes resulted in impaired b-cell function and mass, which can be overcome with exogenous EPO. Our results indicate a critical role for VHL in b-cell function and mass, and that EPO administration improved b-cell function making it a potential strategy for diabetes treatment. KEYWORDS: angiogenesis; b-cell; diabetes mellitus; GLUT2; hypoxia-inducible factor; insulin secretion; von Hippel-Lindau Type 2 diabetes is a disease that is now considered epidemic, as it affects over 200 million people globally, and its prevalence continues to rise despite advances in treatment.
Type 2 diabetes is a disease that is now considered epidemic, as it affects over 200 million people globally, and its prevalence continues to rise despite advances in treatment. 1, 2 The two hallmark characteristics of type 2 diabetes are insulin resistance and b-cell dysfunction. 3, 4 Under insulin-resistant conditions, b-cells undergo a compensation process by expanding b-cell mass and enhancing b-cell function. When b-cell compensation can adequately meet the insulin demands of the body, normoglycemia is maintained. [5] [6] [7] However, in susceptible individuals perhaps with genetic defects and/or environmental insults, the b-cells cannot meet the metabolic demands, ultimately resulting in type 2 diabetes. [8] [9] [10] [11] A previous study by Gunton et al 12 reported results of gene expression profiling analyses on islets of humans with type 2 diabetes, and found a significant decrease in aryl-hydrocarbon-receptor nuclear translocator (ARNT)/hypoxiainducible factor-1b (HIF-1b) expression in these islets. 12 Concomitant with the decrease in ARNT expression was a decrease in HIF-1a expression in the islets of deceased humans with type 2 diabetes. 12 HIFs are the key mediators of cellular adaptation in response to hypoxia. Under conditions of adequate oxygen supply, von Hippel-Lindau tumor suppressor protein (VHL), which makes up a part of the E3-ubiquitin ligase complex, targets HIF-a for ubiquitination and subsequent proteasomal degradation. During hypoxia, the HIF-a subunit is stabilized and translocated to the nucleus, where it binds to the HIF-b/ARNT subunit. The HIF-a/ARNT complex then binds to DNA, resulting in increased transcription of HIF-target genes important for angiogenesis, proliferation, survival, and energy metabolism. [13] [14] [15] [16] It is, therefore, plausible that activating HIF may improve cell survival and also promote beneficial adaptive changes, such as increased angiogenesis. The concept is supported by observations that exposure to hypoxia protects tissues, including the heart, brain, and kidney, from subsequent ischemic injury. [17] [18] [19] We hypothesized that enhanced HIF-a stabilization and HIF-dependent pro-survival gene activation, including vascular endothelial growth factor (Vegf), glucose transporter 1 (Glut1), and erythropoietin (Epo), in the pancreatic b-cells would enhance b-cell mass and improve glucose homeostasis in mice.
MATERIALS AND METHODS Mouse Protocol
RIPcre þ mice 20 were bred to vhlh fl/fl mice 21 (vhlh is the mouse homolog for VHL; Jackson Laboratories) to generate RIPcre þ vhlh þ /fl mice, which were then interbred to generate RIPcre À , RIPcre þ vhlh fl/fl RIPcre þ vhlh þ /fl , and RIPcre þ vhlh þ / þ mice. All mice were maintained on a mixed 129J/ C57BL/6 background, and only RIPcre þ vhlh þ / þ littermates were used as controls. Genotypes for the cre and Vhlh genes were determined by PCR using tail DNA. Primer sequences are available on request. Mice were maintained on a 12-h light-dark cycle with free access to water and standard irradiated rodent chow (5% fat; Harlan Teklad, Indianapolis, IN, USA) and housed in pathogen-free barrier facilities at the central animal facility at the Ontario Cancer Institute (Toronto, Ontario, Canada). All animal experiments were approved by the Ontario Cancer Institute Animal Care Facility.
Metabolic Studies and Hormone Measurements
Blood glucose levels were determined from tail venous blood with an automated glucose monitor (Precision Xtra, Abbott Laboratories, Saint-Laurent, Quebec, Canada). Overnight fasting was approximately 14-16 h in duration. Glucose tolerance tests were performed on overnight-fasted animals by intraperitoneal (i.p.) injection of glucose at a dose of 1 g/kg of body weight, and blood glucose levels were measured at 0, 15, 30, 45, 60, and 120 min post-glucose challenge. Insulin tolerance tests were performed using human regular insulin (Novo Nordisk, Toronto, Ontario, Canada) at a dose of 1 U/ kg of body weight, and blood glucose levels were measured at 0, 15, 30, 45, 60 , and 120 min after the injection of insulin. Glucose-stimulated insulin secretion in vivo was carried out on overnight-fasted animals after an i.p. injection of glucose at a dose of 3 g/kg of body weight, with tail vein blood collected at 0, 2, 10, and 30 min after the injection for insulin measurements. Insulin levels were measured by an enzymelinked immunosorbent assay (ELISA) kit using a rat insulin standard (Crystal Chem, Downers Grove, IL, USA). Islet insulin content was measured by ELISA after acid-ethanol extraction.
Islet Morphometry, Immunohistochemistry, and Immunofluorescent Staining Pancreatic tissue was isolated and fixed in 4% paraformaldehyde in 0.1 M phosphate-buffered saline (pH 7.4). Samples were dehydrated and prepared as paraffin blocks. Thick sections (7 mm) were obtained at 150-mm intervals on three levels and stained for insulin, Ki67, factor VIII (DAKO), cleaved caspase-3 (Cell Signaling), GLUT2 (Millipore), and glucagon (Sigma). Immunofluorescent-stained sections were visualized using a Zeiss inverted fluorescent microscope (Advanced Optical Microscopy Facility, Toronto, Ontario, Canada). Pancreatic sections immunostained for insulin, cleaved caspase-3, and factor VIII were scanned at Â 20 magnification using a ScanScope ImageScope system. The digital images were analyzed with ImageScope version 9.0.19.1516 software (Aperio Technologies, Vista, CA, USA). b-cell area per total pancreatic area was determined in insulin-immunostained pancreatic sections. Endothelial cell immunostaining in the islets with anti-factor VIII and sections immunostained for cleaved caspase-3 were calculated using an automated positive pixel count algorithm and normalized per total islet area. Ki67-positive cells were calculated as a percentage of total islet cells.
Islet Isolation
Pancreatic islets were isolated as previously described. 22 Briefly, 3 ml collagenase (3 mg/ml; Sigma) was injected into the common bile duct to inflate the pancreas. The pancreatic tissue was then removed and digested in collagenase solution at 371C with shaking for 30 min. The digestion was stopped by ice-cold Hanks' balanced salt solution and passed through a filter. Islets were then handpicked under a dissecting microscope.
Western Blotting
Islets, fat, hypothalamus, liver, and muscle tissues were isolated, and protein lysates were obtained as previously described. 23 Lysates were separated by sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis, and immunoblotted with antibodies for VHL (BD Bioscience), Pdx-1, and a-tubulin (Cell Signaling). Western blot signal densities were analyzed using ImageJ software. Protein levels were normalized to a-tubulin levels and expressed in arbitrary units relative to littermate control levels.
mRNA Measurements by Reverse Transcription-PCR (RT-PCR) and Quantitative Real-Time PCR mRNA was extracted from isolated islets by TRIzol following the manufacturer's protocol (Invitrogen, Toronto, Ontario, Canada) and treated with RNase-free DNase (Invitrogen). Semiquantitative RT-PCR amplification was performed with a one-step RT-PCR kit (Invitrogen). Epo, Vegf, and Glut1 were amplified by PCR using specific primers. Densitometric analysis was performed using ImageJ software and normalized to b-actin. Quantitative real-time PCR was performed and quantified by Applied Biosystems 7900 HT Fast RealTime PCR system (Life Technologies Corporation, Carlsbad, CA, USA). Primer sequences are provided in Supplementary  Table S1 .
Recombinant Human EPO (rHuEPO) Treatment rHuEPO (Epoetin-a or Eprex; Ortho-Biotech) was used in all experiments. rHuEPO was diluted in 0.9% NaCl, and mice were injected intraperitoneally three times per week at a dose of 50 mg per kg body weight 24 between 0900 and 1000 hours for 4 weeks.
Statistical Analysis
Data are presented as means±standard errors of the mean, and were analyzed by two-tailed independent samples t-test and one-way analysis of variance with the post hoc Tukey least significant difference test, as appropriate, using the statistical software SPSS (version 17.0 for Windows). P-values of o0.05 were accepted as statistically significant. Figure 1c ). Though we did not detect a significant decrease in VHL expression in the lysates of whole hypothalami in the RIPcre þ vhlh fl/fl mice, the reduced body weight is likely attributed to the VHL deletion in the small subset of insulin-transcribing neurons in the hypothalamus. 25, 26 Indeed, another report, using the same genetic strategy, show that the proportionate growth defect in the RIPcre þ vhlh fl/fl mice is due to reduced pituitary growth hormone production. 27 To confirm that, VHL deletion resulted in enhanced HIF-mediated gene transcription, we performed RT-PCR analyses. HIF-target genes, including Glut1, Vegf, and Epo, were assessed by RT-PCR. Glut1 and Vegf expression levels were increased in the mutant mice compared with controls ( Figure 2a ). Epo gene expression was not present in the islets of either RIPcre þ vhlh fl/fl mice or control littermates ( Figure 2b ). Other HIF-regulated genes were examined by quantitative real-time PCR, including Epo receptor (EpoR), glucokinase (Gck), pyruvate dehydrogenase kinase 1 (Pdk1), and lactate dehydrogenase (Ldha) in islets of RIPcre þ vhlh fl/fl and wild-type mice. In keeping with previous reports, 28, 29 gene expression of EpoR, Pdk1, and Ldha were upregulated, whereas Gck trended lower in islets of RIPcre þ vhlh fl/fl mice compared with wild-type mice ( Figure 9 ). 
RESULTS

Generation of RIPcre
Mice have Impaired Glucose Tolerance To assess the effect of VHL deletion in the pancreatic b-cells on glucose homeostasis, we measured monthly random and fasting blood glucose levels from 1 to 4 months of age. RIPcre þ vhlh fl/fl mice had slightly increased random ( Figure 3a ) and fasting ( Figure 3b ) blood glucose levels compared with control RIPcre þ vhlh þ / þ mice. We then assessed glucose tolerance in 2-month-old mice by performing glucose tolerance tests, which showed impairment in the RIPcre þ vhlh fl/fl mice compared with controls ( Figure 3c ). Next, we investigated whether the glucose intolerance in the RIPcre þ vhlh fl/fl mice was due to peripheral insulin resistance or impaired b-cell function. Insulin tolerance tests showed similar glucose-lowering effects by insulin between RIPcre þ vhlh fl/fl and RIPcre þ vhlh þ / þ mice (Figure 3d ), which suggests that the glucose intolerance in the mutant mice was not due to changes in peripheral insulin sensitivity. Rather, 
of islets per pancreas area was not significantly different between the mutant and wild-type mice (Figure 4b ). We assessed for changes in b-cell proliferation and apoptosis. We immunostained pancreatic sections for Ki67, a marker of proliferation, and found that there was no significant difference in Ki67-positive islet cells between the genotypes (Figure 4c ). Cleaved (activated) caspase-3-immunostained sections also showed no differences in the degrees of apoptosis in the islets between RIPcre þ vhlh fl/fl mice and their control counterparts (Figure 4d) .
b-Cell mass increases with aging as evidenced by the increase in b-cell area per pancreatic area in the RIPcre þ vhlh þ / þ mice in the older 7-to 9-month-old mice compared with their younger counterpart. This age-dependent increase in b-cell mass occurred to a lesser extent in the RIPcre þ vhlh fll/fl mice, resulting in a significantly smaller b-cell area per pancreatic area in the mutant mice compared with RIPcre þ vhlh þ / þ mice in the older age group (Figure 5a ). There was an increase in cleaved caspase-3-positive islet cells in the older RIPcre þ vhlh fl/fl mice compared with their control littermates (Figure 5b ). In addition, we assessed islet cell proliferation in these mice by immunostaining for Ki67 on pancreatic sections. We observed a trend toward a decrease in proliferating b-cells in the RIPcre þ vhlh fll/fl mice compared with RIPcre þ vhlh þ / þ mice (Figure 5c ). Importantly, in either the 2-month-old or the older 7-to 9-month-old RIPcre þ vhlh fll/fl mice, there was no evidence of pancreatic or islet tumors.
Loss of VHL Leads to Decreased GLUT2 Expression in the Islets
We examined whether the defects in b-cell function observed in the RIPcre þ vhlh fl/fl mice were due to reduced insulin or Pdx-1 expression. Interestingly, insulin content of the islets, as assessed by ELISA, showed no differences between the two genotypes ( Figure 6a ). In addition, Pdx-1 protein expression was similar in the islets of RIPcre þ vhlh fl/fl mice compared with control mice (Figure 6b ). However, we observed a significantly reduced expression of GLUT2 at the membrane of the b-cells in the RIPcre þ vhlh fl/fl mice compared with control mice, which suggests that the abnormal glucose tolerance and glucose-stimulated insulin secretion may be due to a defect in the glucose-sensing mechanisms (Figure 6c ). Results represent means ± s.
VHL-Deficient Islets have Enhanced Angiogenesis and Disrupted Morphology
Murine islets have a characteristic architecture, in which the core of the islets consists of insulin producing b-cells, whereas other cell types, a, d, and PP cells are localized around the islet periphery. 30 Interestingly, insulin and glucagon co-immunostaining by immunofluorescence showed disrupted islet morphology with glucagon-positive a cells scattered throughout the core of the islets in RIPcre rHuEPO Administration Rescues the Glucose Intolerance and b-Cell Dysfunction in RIPcre þ vhlh fl/fl Mice The induction of hypoxia leads to the upregulation of various hypoxia-inducible genes, including Epo, Vegf, and Glut1, which by-in-large provide pro-survival functions. [13] [14] [15] [16] 31, 32 Accordingly, RT-PCR analyses on isolated islets from the RIPcre þ vhlh fl/fl mice showed enhanced gene expression of Vegf and Glut1 in the RIPcre þ vhlh fl/fl mice compared with controls ( Figure 2a) . Epo gene expression is well documented to be produced by the peritubular fibroblasts of the kidney 33 and the hepatocytes. 34 In addition, recent studies have shown its production in other tissues, including the brain, heart, and uterus. 35 However, Epo gene expression was not present in the islets of RIPcre þ vhlh þ / þ mice, and furthermore, no upregulation was observed in the RIPcre þ vhlh fl/fl mice (Figure 2b ). Given that EPO has been shown to promote prosurvival and proliferative signaling, 36 and that EPO receptor is present in pancreatic b cells, 37 we tested whether providing immunostaining showed a trend toward a decrease in islet proliferation in the mutant mice compared with controls, n ¼ 3 per genotype. *Po0.05. (Figure 8e ), which suggests that the improved glucose tolerance observed in rHuEPO-treated RIPcre þ vhlh fl/fl mice may be due to enhanced insulin secretion rather than an increase in b-cell mass.
To assess whether the enhanced insulin secretion is because of the improvement in glucose-sensing abilities in rHuEPO-treated RIPcre þ vhlh fl/fl mice, we examined their GLUT2 expression. Interestingly, GLUT2 expression was restored in the islets of rHuEPO-treated RIPcre þ vhlh fl/fl mice as assessed by immunofluorescence (Figure 8d ). Gene expression measurements using quantitative real-time PCR also showed increased levels of Glut2 in rHuEPO-treated RIPcre þ vhlh fl/fl mice compared with salinetreated RIPcre þ vhlh fl/fl mice ( Figure 9 ). Effects of rHuEPO on other HIF-regulated genes were also measured. Interestingly, rHuEPO treatment completely reversed some transcriptional changes that were present in islets of RIPcre þ vhlh fl/fl mice, such as EpoR and Pdk1. Gck on the other hand was increased in both RIPcre þ vhlh fl/fl and wild-type mice after rHuEPO treatment, whereas partial normalization was achieved with Glut2 and Ldha in islets of RIPcre 
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DISCUSSION
The VHL tumor suppressor has an essential role in the cellular response to hypoxia. 38 To gain insight into the role of VHL in b-cell homeostasis, we have specifically deleted VHL in b-cells using the Cre-loxP recombination system. The resultant RIPcre þ vhlh fl/fl mice exhibited proportionate small body size that was also found by another group, which was not related to adiposity. 27 VHL gene was first described as a tumor suppressor from inactivation mutations in familial studies, which showed a variety of malignant and benign tumors of the eye, brain, spinal cord, kidney, pancreas, and adrenal glands, known as VHL. 39 In our studies, the b-cell-specific VHL-knockout mice, in which cre-mediated VHL deletion was under the control of the RIP, did not demonstrate any evidence of tumor development, similar to a study by Cantley et al. 27 In addition, in this study, mice in which VHL was deleted under the control of the Pdx-1 promoter (Tg (Pdx1-cre) 1Herr) was used, which also demonstrated a glucose intolerant phenotype due to impaired insulin secretion. However, another study by Shen et al 40 showed that mice with Pdx-1-driven VHL deletion in a different genetic background (Tg (Pdx1-cre) 89.1Dam) resulted in tumor development and early mortality.
Contrary to our initial hypothesis, in which the increased HIF-mediated gene transcription by VHL deletion in the b-cells would increase b-cell mass and function, our study demonstrates a defect in b-cell function resulting in glucose intolerance. This is in keeping with other studies, which all show a defect in b-cell function as a result of VHL loss. 27, 41, 42 Importantly, however, these studies did not show a defect in b-cell mass. In contrast to these studies, we are the first to show that VHL has a critical role in b-cell growth that occurs with aging. As such, the older RIPcre þ vhlh fl/fl mice (7-9 months) exhibit a compromised age-dependent growth in b-cell mass, resulting in reduced b-cell mass compared with control littermates in the older cohort. This is likely due to enhanced apoptosis as evidenced by increased cleaved 
caspase-3 immunostaining in the islets in the older mutant mice. These results show the importance of the HIF pathway in modulating apoptosis, which allow for the increase in the b-cell mass that occurs with aging. 43, 44 Recent published studies indicate that both of oxygen tension and hypoxia are critical regulators for b-cell development. 45, 46 At E11.5-E13.5 of embryogenesis, hypoxiainduced HIF1-a/Notch signaling is important for the Results represent means ± s.
proliferation of endocrine progenitor cells. Later, at approximately E13.5, angiogenesis mediated by HIF1-a-encoding VEGF is necessary for increased oxygenation in endocrine tissue, which then destabilizes HIF1-a through degradation. Suppression of HIF1-a at this stage is essential for the normal differentiation of pancreatic islets. As such, persistent expression of HIF1-a during embryogenesis would suppress the transcription factor neurogenin 3, 46 which is critical for endocrine differentiation. 47 Collectively, the imbalance of HIF can affect the development of pancreas, and contribute to glucose intolerance and b-cell dysfunction.
Loss of VHL has profound effects on b-cell function, demonstrating a role for VHL in regulating glucose homeostasis by alterations in expression of HIF-regulated genes. The mutant mice had decreased GLUT2 expression in their b-cells, which is in keeping with previously published studies. 27, 41 Decreased expression of GLUT2 has been reported in several animal models of diabetes. 48, 49 In addition, mice with GLUT2-deficient b-cells also have impaired insulin secretion, leading to diabetes development. 50 Therefore, defective glucose-sensing likely has a significant role in the impairment of b-cell function that is present in the VHL mutant mice. In addition to the changes observed within the VHL-deficient b-cells, there were significant alterations in islet architecture caused by increased vasculature likely due to Vegf upregulation, which may have influenced b-cell function. Indeed, an abnormal islet vascular bed and a twofold increase in vascular density were also reported in both prediabetic and diabetic male Zucker diabetic fatty rat compared with control mice. 51 Deletion of VHL leads to the enhanced transcription of canonical HIF-target genes that promote cell and tissue survival, including Epo, Vegf, and Glut1, which led us to initially hypothesize that VHL deletion in the b-cells would provide cytoprotective effects. On the contrary, loss of VHL impaired insulin secretion in the b-cells, which may arise from stabilized HIF expression during pancreas development. 45, 46 Indeed, previous studies have shown that hypoxia impairs insulin secretion. 52, 53 Thus, these studies along with our findings and others, 27, 41, 42 which all show impaired b-cell function with VHL loss, are in contrast to the results by Gunton et al, 12 which suggests that a reduction in HIF expression in the islets contributes to the b-cell dysfunction in type 2 diabetes. 12 In the same study, it was reported that knockdown of HIF-1a in Min6 cells leads to impaired glucose-stimulated insulin secretion. 12 In the Gunton et al study, b-cell-specific ARNT deletion led to impaired insulin signaling in the b-cells, 14 whereas VHL deletion in the b-cells led to defects in glucose uptake and metabolism, 27,41,42 both of which are critical processes for efficient insulin secretion. 54 These results exemplify the complex nature of both HIF-1a and HIF-1b in regulating b-cell function and mass, and further work is required for a more clear understanding of HIF biology in b-cells.
The Epo gene is one of the major hypoxia-inducible genes, 31 and although it is expressed in many tissues (reviewed in Wijesekara et al 23 ), it appears not to be present in pancreatic islets. Interestingly, overexpression of Epo in pancreatic islets was shown to have cytoprotective effects. 55 We, therefore, assessed whether providing exogenous EPO by systemic rHuEPO administration could improve the glucose tolerance in the RIPcre þ vhlh fl/fl mice. Indeed, rHuEPO treatment for 4 weeks improved glycemic control in the RIPcre þ vhlh þ / þ and RIPcre þ vhlh fl/fl mice compared with their saline-treated counterparts. rHuEPO treatment was shown to activate the PI3K signaling pathway in isolated islets (D Choi, M Woo, unpublished data). In the VHL mutant mice, rHuEPO was able to rescue the defects in b-cell function perhaps by enhancing the glucose-sensing abilities through restoring GLUT2 and Gsk expression. rHuEPO treatment also reversed expression of the anaerobic glycolytic enzymes, Pdk1 and Ldha, which may rescue glucose metabolism and insulin secretion. Previous studies demonstrated that HIF degradation could also be mediated by VHL-independent mechanisms, such as Hsp90, 56 RACK1, 57 Gsk3, 58 and Hsp70. 59 Interestingly, EPO has been shown to activate Gsk3 60 and Hsp70, 61 which can in turn alter HIF-regulated genes in islets of RIPcre þ vhlh fl/fl mice. rHuEPO treatment also reversed expression of the anaerobic glycolytic enzymes, Pdk1 and Ldha, which may rescue glucose metabolism and insulin secretion. 
